AU691284B2 - Novel hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same - Google Patents
Novel hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same Download PDFInfo
- Publication number
- AU691284B2 AU691284B2 AU24161/95A AU2416195A AU691284B2 AU 691284 B2 AU691284 B2 AU 691284B2 AU 24161/95 A AU24161/95 A AU 24161/95A AU 2416195 A AU2416195 A AU 2416195A AU 691284 B2 AU691284 B2 AU 691284B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- formula
- compounds
- document
- date
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002253 acid Substances 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 9
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 8
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 125000003118 aryl group Chemical group 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- 239000001301 oxygen Substances 0.000 claims abstract description 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 4
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 19
- -1 nitro, amino Chemical group 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 229910000039 hydrogen halide Inorganic materials 0.000 claims description 3
- 239000012433 hydrogen halide Substances 0.000 claims description 3
- KWAJJEZBUDILEM-UHFFFAOYSA-N n'-(2-piperidin-1-ylethoxy)pyridine-3-carboximidamide Chemical compound C=1C=CN=CC=1C(=N)NOCCN1CCCCC1 KWAJJEZBUDILEM-UHFFFAOYSA-N 0.000 claims description 3
- AGTGHCHNQBZRFA-UHFFFAOYSA-N n'-(3-morpholin-4-ylpropoxy)pyridine-3-carboximidamide Chemical compound C=1C=CN=CC=1C(=N)NOCCCN1CCOCC1 AGTGHCHNQBZRFA-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- DRDAVOZQPPTAAS-UHFFFAOYSA-N n'-methoxypyridine-3-carboximidamide Chemical compound CONC(=N)C1=CC=CN=C1 DRDAVOZQPPTAAS-UHFFFAOYSA-N 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 230000003595 spectral effect Effects 0.000 claims description 2
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims 1
- 238000006826 Stephen synthesis reaction Methods 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 abstract description 3
- 230000000302 ischemic effect Effects 0.000 abstract description 3
- 230000002253 anti-ischaemic effect Effects 0.000 abstract description 2
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 2
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 67
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- 239000000203 mixture Substances 0.000 description 29
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 25
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 238000003756 stirring Methods 0.000 description 20
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 13
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 13
- 235000010288 sodium nitrite Nutrition 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 239000003463 adsorbent Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229940102223 injectable solution Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- MMWRGWQTAMNAFC-UHFFFAOYSA-N 1,2-dihydropyridine Chemical compound C1NC=CC=C1 MMWRGWQTAMNAFC-UHFFFAOYSA-N 0.000 description 2
- HDDNBUNZJIQDBQ-UHFFFAOYSA-N 1-(3-chloropropyl)piperidine Chemical compound ClCCCN1CCCCC1 HDDNBUNZJIQDBQ-UHFFFAOYSA-N 0.000 description 2
- YBKOPFQCLSPTPV-VMPITWQZSA-N 3-pyridine aldoxime Chemical compound O\N=C\C1=CC=CN=C1 YBKOPFQCLSPTPV-VMPITWQZSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 201000009101 diabetic angiopathy Diseases 0.000 description 2
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000989 food dye Substances 0.000 description 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- XTHKQERSQXQQCR-UHFFFAOYSA-N n'-(2,2-dimethyl-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide Chemical compound C1CCCCN1CC(C)(C)CONC(=N)C1=CC=CN=C1 XTHKQERSQXQQCR-UHFFFAOYSA-N 0.000 description 2
- GHQIOIADCHFOGN-UHFFFAOYSA-N n'-(3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide Chemical compound C=1C=CN=CC=1C(=N)NOCCCN1CCCCC1 GHQIOIADCHFOGN-UHFFFAOYSA-N 0.000 description 2
- WZRCABZOYOJJGM-UHFFFAOYSA-N n'-[3-(4-methylpiperazin-1-yl)propoxy]pyridine-3-carboximidamide Chemical compound C1CN(C)CCN1CCCONC(=N)C1=CC=CN=C1 WZRCABZOYOJJGM-UHFFFAOYSA-N 0.000 description 2
- AQBMQGDKWIPBRF-UHFFFAOYSA-N n'-hydroxypyridine-3-carboximidamide Chemical compound ON=C(N)C1=CC=CN=C1 AQBMQGDKWIPBRF-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000002972 tibial nerve Anatomy 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- VFLQQZCRHPIGJU-UHFFFAOYSA-N 1-(2-chloroethyl)piperidine;hydron;chloride Chemical compound Cl.ClCCN1CCCCC1 VFLQQZCRHPIGJU-UHFFFAOYSA-N 0.000 description 1
- ZYHFENPBZWCKFE-UHFFFAOYSA-N 1-(3-chloro-2,2-dimethylpropyl)piperidine;hydrochloride Chemical compound Cl.ClCC(C)(C)CN1CCCCC1 ZYHFENPBZWCKFE-UHFFFAOYSA-N 0.000 description 1
- AUERUDPETOKUPT-UHFFFAOYSA-N 1-(3-chloropropyl)-4-methylpiperazine Chemical compound CN1CCN(CCCCl)CC1 AUERUDPETOKUPT-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- PKQNKYFGYUTJHB-UHFFFAOYSA-N 3-nitro-n'-(3-piperidin-1-ylpropoxy)benzenecarboximidamide Chemical compound [O-][N+](=O)C1=CC=CC(C(=N)NOCCCN2CCCCC2)=C1 PKQNKYFGYUTJHB-UHFFFAOYSA-N 0.000 description 1
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101100460584 Chaetomium thermophilum (strain DSM 1495 / CBS 144.50 / IMI 039719) NOC1 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- MDNFGNHIELARIM-UHFFFAOYSA-N Cl.Cl.Cl.C1CN(C)CCN1CCCON=C(Cl)C1=CC=CN=C1 Chemical compound Cl.Cl.Cl.C1CN(C)CCN1CCCON=C(Cl)C1=CC=CN=C1 MDNFGNHIELARIM-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 101000716740 Homo sapiens SR-related and CTD-associated factor 4 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910004013 NO 2 Inorganic materials 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102220472514 Protein ENL_H18R_mutation Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100020878 SR-related and CTD-associated factor 4 Human genes 0.000 description 1
- 101100022229 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MAK21 gene Proteins 0.000 description 1
- 101100313929 Schizosaccharomyces pombe (strain 972 / ATCC 24843) tip1 gene Proteins 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- IAHMNSCQDXESII-UHFFFAOYSA-N benzenecarboximidoyl chloride Chemical compound ClC(=N)C1=CC=CC=C1 IAHMNSCQDXESII-UHFFFAOYSA-N 0.000 description 1
- 150000008359 benzonitriles Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- XEKAUTDWPYQNFU-UHFFFAOYSA-N chlorane Chemical compound Cl.Cl.Cl XEKAUTDWPYQNFU-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000001034 iron oxide pigment Substances 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SBGBSARAGZEWGI-UHFFFAOYSA-N n'-hydroxy-3-(trifluoromethyl)benzenecarboximidamide Chemical compound ON=C(N)C1=CC=CC(C(F)(F)F)=C1 SBGBSARAGZEWGI-UHFFFAOYSA-N 0.000 description 1
- SOEBOUPZOVWSHT-UHFFFAOYSA-N n'-methoxypyridine-3-carboximidamide;hydrochloride Chemical compound Cl.CONC(=N)C1=CC=CN=C1 SOEBOUPZOVWSHT-UHFFFAOYSA-N 0.000 description 1
- ZJFSLWHOVWKJTI-UHFFFAOYSA-N n'-phenylmethoxypyridine-3-carboximidamide;hydrochloride Chemical compound Cl.C=1C=CN=CC=1C(=N)NOCC1=CC=CC=C1 ZJFSLWHOVWKJTI-UHFFFAOYSA-N 0.000 description 1
- RAXWUDYAOLECEY-UHFFFAOYSA-N n-phenylmethoxypyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NOCC1=CC=CC=C1 RAXWUDYAOLECEY-UHFFFAOYSA-N 0.000 description 1
- MRMXDFQCXZFIQR-UHFFFAOYSA-N n-phenylmethoxypyridine-3-carboximidoyl chloride;hydrochloride Chemical compound Cl.C=1C=CN=CC=1C(Cl)=NOCC1=CC=CC=C1 MRMXDFQCXZFIQR-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000010289 potassium nitrite Nutrition 0.000 description 1
- 239000004304 potassium nitrite Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- FVGUUJNEJJPLCS-UHFFFAOYSA-N pyridine-3-carboximidamide Chemical compound NC(=N)C1=CC=CN=C1 FVGUUJNEJJPLCS-UHFFFAOYSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- JXAZAUKOWVKTLO-UHFFFAOYSA-L sodium pyrosulfate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)OS([O-])(=O)=O JXAZAUKOWVKTLO-UHFFFAOYSA-L 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/02—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
- C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
Abstract
PCT No. PCT/HU95/00014 Sec. 371 Date Nov. 5, 1996 Sec. 102(e) Date Nov. 5, 1996 PCT Filed May 4, 1995 PCT Pub. No. WO95/30649 PCT Pub. Date Nov. 16, 1995Hydroximic acid derivatives possess anti-ischemic effects, and therefore, they are useful for treating ischemic states and diseases, such as myocardial ischemia (which may be induced by occlusion of coronary arteries). These derivatives include compounds of formula (I): wherein: X represents a halogen; Z represents an aromatic group, a pyridinyl group, a picolyl group, or a lutidyl group; and R represents an -A-N(R1)R2 group, wherein: R1 and R2 represent, independently from each other, hydrogen or an alkyl group; or R1 and R2, together with the adjacent nitrogen atom, form a 5- to 7-membered, saturated heterocyclic group optionally containing an additional nitrogen, oxygen, or sulfur atom, the heterocyclic group optionally being substituted by at least one alkyl group; and A represents a straight or branched chain alkylene group, as well as pharmaceutically acceptable acid addition salts thereof. The invention further relates to processes for preparing the above noted compounds, and pharmaceutical compositions containing these compounds or their pharmaceutically acceptable acid addition salts as an active ingredient. Additionally, the invention relates to intermediate compounds of formula II used in preparing the compounds of formula I. Formula II is as follows: In formula II, the variables Z and R have the same definitions provided above.
Description
WO 95/30649 PCT/HU95/00014 NOVEL HYDROXIMIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME The invention relates to novel, biologically active hydroximic acid derivatives of the formula
/X
Z- C
ZN-OR
wherein X means halogen; Z stands for an aromatic group, pyridinyl group or the like; and R represents an alkyl or phenylalkyl group or an -A-N(R 1
)R
2 group, and in the latter
R
1 and R2 stand, independently from each other, for hydrogen or alkyl group; or R 1 and R 2 together with the adjacent nitrogen atom, form a 5- to 7-membered, saturated heterocyclic group optionally containing an additional nitrogen, oxygen or sulfur atom, said heterocyclic group optionally being substituted by at least one alkyl group; and A stands for a straight or branched chain alkylene group, as well as their pharmaceutically acceptable acid addition salts and pharmaceutical compositions containing these compounds. Furthermore, the invention relates to a process for the preparation of the above compounds and to a method for the treatment of ischaemic states or diseases in mammals, including men.
I I- IL WO 95/30649 PCT/HU95/00014 -2- X as halogen means fluorine, chlorine, bromine or iodine; compounds containing chlorine as X are preferred.
Z as an aromatic group is preferably a phenyl, phenylalkyl, substituted phenyl, substituted phenylalkyl group or naphthyl group. The phenyl group of the above substituted groups may be substituted by 1 to 3 identical or different group(s), which is (are) suitably halogen, haloalkyl, alkyl, hydroxy, alkoxy, nitro, amino, mono- or dialkylamino groups.
The term "Z stands for a pyridinyl group or the like" means a pyridinyl group or its homologues, e.g. picolyl or lutidyl group. Pyridinyl group is particuo1 larly preferable; whereas 3-pyridinyl group proved to be most advantageous.
Above and in the forthcoming, alkyl or alkoxy groups as R, R 1 and R2 or as substituents contain preferably 1 to 8, suitably 1 to 6, most preferably 1 to 4 carbon atoms unless stated otherwise. Methyl, ethyl or n-propyl groups are most preferred.
Thus, phenylalkyl group is in most cases benzyl or phenethyl group; whereas the mono- and dialkylamino groups are preferably monoC1.4alkyl or diC1-4alkyl groups, respectively.
The haloalkyl group may contain one or more above-mentioned halogen(s) or it may be a perfluoroalkyl group. Preferred are e g. the chloromethyl, 2chloroethyl or trifluoromethyl groups.
The heterocyclic group formed by R 1
R
2 and the adjacent nitrogen together is preferably piperidino, piperazino or morpholino group. These groups may optionally be substituted by at least one alkyl group defined above. Thus, these groups may be e.g. a 4-methylpiperazinyl or 2,2-dimethylpiperidinyl group.
The alkylene group A may contain a straight or branched chain, and suitably it contains 1 to 8, preferably 1 to 5 carbon atoms. The 1,2-ethylene, 1,3-propylene and 1,4-butylene groups are especially advantageous.
All compounds of the formula are novel. A part of the starting materials for their preparation is known whereas others are new. The methods of prepara- I I I I la tion of the new starting materials are described in the corresponding examples.
Insecticides being structurally similar to the compounds of the formula (I) are disclosed in the Japanese patent application published under No. 60.0008253 (Kokai) as well as P-blocking agents being structurally similar to the compounds of the formula are claimed in the European patent specification No.
0,147,210.
Structurally, the compounds disclosed in the latter document differ from the compounds of formula in that a -CH 2 -CH(OH)-CH2-(2-hydroxy-propylene) moiety is present between the terminal -NR 1
R
2 group and the remaining part of the molecule instead of the unsubstituted straight or branched alkylene group symbolized by A in the compounds of the formula The compounds described in the European patent specification 0,417,210 are diabetes selective B-antagonists and can be used especially in the therapy of diabetic angiopathy.
Beltrao, T. M. et al describe the preparative and spectroscopic investigation of Omethylbenzamidoximes of the formula p-Rl-C 6
H
4 -C(NH2)-NOR (R=Me, R 1 H, Me, Cl, Br, NO 2 in their article "Preparation and spectral study of O-methylbenzamidoximes" [An. Acad. Bras. Cienc.1978, (50)2,159-64]. The synthetic route described is traditional, starting with addition of hydroxylamine to a substituted benzonitrile, followed by O-methylation with Me 2 SO4. Beside the investigation of the tautomerism of the products in solution by IR spectroscopy it is also described that some of the 0methylbenzamidoximes was found to be active against Trypanosoma cruzi.
The structurally closest analogues of compounds of formula from the prior art are the classical 13-adrenerg receptor antagonists, more specifically the family of the 3blocker aryloxypropanolamine derivatives. These compounds always possess a secondary hydroxyl group in their alkylene moieties binding the terminal -NR 1
R
2 group to the molecule, and the SAR studies have clearly demonstrated that this substructure is essential for their biological activity [see in this respect e.g. Comprehensive Medicinal Chemistry (ed. C. Hansch), Vol. 3. "Membranes and Receptors" (ed. J. C. Emmett), Pergamon Press, 1990, pp. 199,200 and 206]. It has to be noted that the presence of this hydroxyl group introduces chirality to the structure of these compounds.
ENDED SHEET
__MEW
i Ge o 0O;r- 0, O 01 C *i 6 0 0 00 gg a 8* 0 *0 0 00 0 00 i 0 0 0 0 O0 Q 0 r However, it is always desirable that compounds for medicinal use have the simplest possible structure that makes their preparation and biological investigation easy.
Recently researchers have been seeking particularly for molecules without chirality in order to avoid the laborious and expensiv'q vestigation of the stereoisomeric forms and their mixtures, required more and more by the registration authorities in the last few years. However, based of the similarities between both the chemical structures and the biological effect of the above mentioned B-blockers and the compounds described in the cited EP 0,417,210 patent specification, it could be expected that omitting the hydroxyl group from latter derivatives should result in loss of their biological activity as well.
Surprisingly, we have found that compounds of formula i.e. hydroximic acid derivatives having an aminoalkyl portion that contains no hydroxyl functionality, possess therapeutically valuable biological activity, consequently, they are useful as active ingredients in medicaments. Based on this recognition the invention provides biologically active chemical substances that can be prepared and biologically assessed without the difficulties typically arising at the closely related optically active compounds.
The compounds of the formula can be prepared by using several known processes from which the following ones will be described without intending any* limitation as to the scope claimed.
a) A compound of the formula _NH2 Z C OR(
N-OR
wherein Z and R are as defined form formula or an acid addition salt thereof is treated with a diazotizing agent known per se in the presence of a hydrogen halide.
Alkali metal nitrites g. sodium or potassium nitrite) or an alkyl nitrite (e.g.
isoamyl nitrite or tert-butyl nitrite) are useful diazotizing agents in the presence of a hydrogen halide hydrochloric acid, hydrogen bromide or the like). After carrying out the reaction at a temperature between -5°C and 15 0 C, the mixture is stirred until decomposition of the transitorily formed diazonium salt, preferably for 10 to 60 minutes.
b) A compound of the formula X z \N OH wherein X and Z are as defined for the formula is reacted with a compound of the "'<AMNDED SHEEf ~ycr .~i6r -4formula R Y (IV), wherein R is as defined above and Y means a leaving group. This reaction is carried out at room temperature in the presence of an acid binding agent.
c) A compound of formula Z- C NH OR or formula Z CH NOR
(VI),
respectively, wherein Z and R are as defined above, is treated with a suitable halogenating agent.
For halogenation of the compounds of the formula e.g. thionyl chloride, phosphorus pentahalides, phosphorus oxyhalides, phosgene, carbon tetrachloride/triphenylphosphine, hydrogen fluoride/pyridine, diethylamino-sulfur-trifluoride and the like are useful. The reaction is carried out at an elevated temperature, suitably at the boiling point of the reaction mixture.
For halogenation of the compounds of the formula (VI) elemental halogens chlorine or bromine) hypohalogenites sodium hypohalogenite, tertbutyl hypohalogenite) or N-chlorosuccinimide, N-bromosuccinime and the like are useful. The reaction is carried out in the presence of an organic solvent, e.g.
chloroform or benzene, suitably at room temperature.
d) Alternatively, if it is desired to prepare a compound containing an
-A-N(R
1
)R
2 group as R, belonging therefore to a narrower group of the compounds of the formula an amine of the formula HN(R 1
)R
2 wherein R 1 and R2 are as defined for the formula is reacted with a compound of formula
X
Z C (VII),
N-O-A-Y
wherein Z, X, Y and A are as defined above. This reaction is performed in an organic solvent.
M A AMENDED S1EET m WO 95/30649 PCT/ITU95/00014 If desired, the compounds of the formula prepared by using any of the processes c) or respectively, can be converted to pharmaceutically acceptable acid addition salts in a manner known per se.
During our investigations on the compounds prepared it has been found that they possess anti-ischaemic effect.
The reperfusion-induced arrhythnma [ventricular tachycardia (VI) and ventricular fibrillation was studied on anaesthetized rats. The myocardial ischaemia was elicited by compressing the left-sided descending coronary artery for 5 minutes and after the ceasing thereof, by a 10-minute reperfusion of the 0o heart. ECG was continuously monitored and the change of the mean duration of VT and VF under effect of the test compounds as well as the survival were measured in the first 3 minutes of reperfusion. The test compounds were administered in an intravenous dose of 1 mg/kg by 5 minutes before compressing the left-sided descending coronary artery. The survival of experimental animals was found to be 100% by using e.g. the compounds of Examples 2 and 7.
The vasorelaxant effect of the compounds was investigated in vitro on the thoracal aorta isolated from rabbit [Am. J. Physiol. 257, 1327-1333 (1989)]. Our results are summarized in Table 1.
Table 1 Compound No. 2 4 5 6 7 8 9 Ref
EC
5 0 (x10- 5 M) 2.7 8.2 2.4 1.3 0.6 1.5 7.6 8.3 Reference drug: Bepridil [Eur. J. Pharm. 166, 241-249 (1989)].
The number of compounds is given as number of the corresponding Example in the present patent application.
Furthermore, the effect of compounds of the invention in the treatment of complications associated with the diabetic angiopathy was studied. The in vivo action was measured on rats, by the change of rate of the impulse conduction in an STZ-induced diabetic state as follows.
The rate of motor and sensory impulse conduction (MCR or SCR, respect- LII BI~-nrCI~ ICI--Ya~-- -6ively) of the sciatic and tibial nerve, respectively, as mixed type nerves was determined by using the method of E. F. Stenley [Experimental Neurology 71, 497- 506 (1981) as modified by P. De Koning and W. H. Gispen: Peptides 8, 415-412 (1987)]. The electrophysiological measurements were carried out on anaesthetized male Cr:Wistar rats at the end of a one-month period of treatment with mg/kg administered orally The sciatic or tibial nerve, respectively, was excited by needle electrodes stitched near the nerve on the lower extremity and the electromyographic (EMG) responses of the plantar muscle were registered.
Five EMG-s each were averaged and the results were stored in a computer. The 1t latency periods of the motor and sensory components were measured. The rates of impulse conduction were calculated from the ratio of the distance between two sites of excitation to the differences of latency.
The reduced impulse conduction of the diabetic animals was restored by the compounds investigated in the following percentage values: Compound No. MCR correction SCR correction 2 100 100 7 48 64 Reference drug* 40 50 mg/kg of aminoguanidine The active compounds of the invention can be administered mainly by oral or parenteral route, e.g. in a daily dose of 1-10 mg/kg body weight to an adult human.
For the preparation of oral compositions e.g. lactose or starch may be used as filling material. Gelatine, (carboxymethyl)cellulose sodium, methyl cellulose, polyvinylpyrrolidine or starch gum are useful binding or granulating agents. Potato starch or microcrystalline cellulose are mainly added as disintegrating agents though ultraamylopectin, formaldehyde-casein and the like are also suitable. Use- AMENDED SHEET Ir ,I WO 95/30649 PCT/HU95/00014 -7ful anti-adhesive and sliding materials are talc, colloidal silicic acid, stearin, calcium or magnesium stearate or the like.
Tablets can be prepared e.g. by wet granulation and subsequent compression. After mixing the active components and excipients as well as optionally a part of the disintegrating additive they are granulated together with the aqueous, alcoholic or aqueous-alcoholic solution of the binding agent in a suitable equipment, then the granular substance is dried. Thereafter, the other disintegrating, sliding and antiadhesive auxiliaries are mixed to the dried granulate and the mixt xe is compressed to tablets. Optionally the tablet is provided with a groove to for facilitating the administration. Tablets can directly be prepared also by compression from a mixture of the active ingredient and suitable auxiliaries. If desired, the tablets may be converted to drag6es by using additives commonly employed for the preparation of medicaments such as stabilizing, savouring agents and dyes, e.g. sugar, cellulose derivatives [methyl- or ethylcellulose, (carboxymethyl)cellulose sodium and the like], polyvinylpyrrolidone, calcium phosphate, calcium carbonate, food dyes, food dye lacquers, aromatizing agents, iron oxide pigments and the like.
For the preparation of capsules, a mixture containing the active ingredient(s) and auxiliaries is filled into capsules.
For parenteral administration the composition is formulated to an injectable solution. For preparing such a solution the active ingredients are dissolved in distilled water and/or various organic solvents, e.g. glycol ethers, optionally in the presence of solubilizing agents such as polyoxyethylene sorbitan monolaurate, monooleate or monostearate (Tween 20, Tween 60 or Tween 80, respectively). In addition, the injectable solution may contain various auxiliaries, e.g.
preserving agents such as benzyl alcohol, methyl or propyl p-hydroxybenzoate, benzalkonium chloride or phenyl mercury borate and the like; as well as antioxidants, e.g. ascorbic acid, tocopherol, sodium pyrosulfate and optionally complexforming substances such as ethylenediamine tetraacetate for binding metal traces; furthermore pH-adjusting agents and buffers as well-as optionally, a local anaes- WO 95/30649 PCT/HU95/00014 -8thetic such as lidocaine. Before filling the injectable solution containing the composition of the invention into the ampoule, the solution is filtered and after filling in, it is sterilized.
The invention also relates to a method for the treatment of ischaemic states or diseases. This method comprises administering a therapeutically effective amount of an active compound of formula or a pharmaceutically acceptable acid addiion salt thereof to the patient.
The vention relates also to certain novel intermediates of formula (II); from which the following ones are preferred: 0o N-(3-piperidino-l-propoxy)-3-pyridinecarboxamidine, N-methoxy-3-pyridinecarboxamidine, N-(3-morpholinopropoxy)-3-pyridinecarboxamidine, N-(2-piperidinoethoxy)-3-pyridinecarboxamidine, N-[3-(1-piperidinyl)-propoxy]-3'-(trifluoromethyl)benzamidine, N-[3-(4-methylpiperazin-1-yl) 1-propoxy]-3-pyridinecarboxamidine, N-(2,2-dimethyl-3-piperidinopropoxy)-3-pyridinecarboxamidine and acid addition salts of the:e compounds.
The invention is illustrated in more detail by the following non-limiting Examples.
Example 1 Preparation of N-benzyloxy-3-pyridinecarboximidoyl chloride hydrochloride A) A solution containing 6.38 g (26.7 mmoles) of N-benzyloxy-3-pyridinecarboxamidine hydrochloride in the mixture of 27.4 ml of concentrated hydrochloric acid and 73 ml of water is cooled to 5"C and 2.29 g (33.2 mmoles) of sodium nitrite dissolved in 13 ml of water are dropwise added. The mixture is stirred at this temperature for additional 30 minutes. After layering 50 ml of chloroform to the mixture, it is alkalinized to pH 8 to 9 by adding solid sodium carbonate. After separation of the chloroformic phase, the aqueous phase is again extracted twice with 50 ml of chloroform each, then the combined chloroformic -9solution is washed with 10 ml of saturated saline solution, dried over anhydrous sodium sulfate and evaporated.
The residue obtained (5.49 g, 79%) is dissolved in 55 ml ofisopropanol and ml of a 2.1 molar solution of hydrogen chloride in isopropanol are added to obtain the hydrochloride salt of the product in a yield of 3.88 g 146- 151.5 *C (recrystallized from methanol/ether).
1 H-NMR (DMSO): 9.1-8.8 (broad, 1H, 9.07 1H), 8.90 (dd, 1H), 8.56 1H), 7.9 (dd, 1H pyridine 7.5-7.3 5H Ph), 5.38 2H
CH
2 ppm.
13 C-NMR (DMSO):146.4, 142.3, 139.2, 129.8, 125.8 (pyridine 2-6-4-3-5), 133.0 135.9, 128.5, 128.3, 128.2 77.3 (CH 2 ppm.
Elementar analysis for C 13
H
11 NOC1.HCI: calculated: C 55.1; H 4.3; N 9.9; Cl 25.0%; S. found: C 55.0; H 4.2; N 10.1; Cl 25.2%.
15 B) 2,38 g (10 mmoles) of N-(benzyloxy)nicotinamide (Beilstein 22/V, page 120) are boiled under reflux in 20 ml of thionyl chloride for 2 hours. After distilling off the excess of thionyl chloride, the residue is crystallized from isopropanol to give 1.75 of the desired product, the physical characteristics of which are identical to those of the product prepared by method A).
Example 2 Preparation of N-(3-piperidinopropoxy)-3-pyridinecarboximidoyl *o chloride dihydrochloride A) After cooling to 0°C a mixture of 10 ml of distilled water and 4.36 ml of concentrated hydrochloric acid, 2 g (7.62 mmoles) of N-(3-piperidino-l-propoxy)-3-pyridinecarboxamidine are added under stirring. To the yellow solution 2.7 g (3.81 mmoles) of sodium nitrite dissolved in 10 ml of water are added dropwise at -5 0 C during 30 minutes. After stirring the greenish solution at -5 0
C
for 1.5 hours, the pH of the solution is adjusted to 10 by adding 1 N aqueous sodium hydroxide solution under cooling, then the solution is extracted 3 times SRA4 7 -2 yj WO 95/30649 PCT/HU95/00014 with 40 ml of chloroform. The organic phase is washeu wvith 20 ml of water, dried over sodium sulfate and evaporated. The residue is purified by column chromatography (Merck Kieselgel 60; eluent: chloroform/methanol 1:1) to obtain 1.7 g of the base corresponding to the title compound.
The title hydrochloride is prepared from the base obtained by adding an ethanolic solution of hydrogen chloride, 165-167 0
C.
IR (KBr) y cm-1: 3015, 2945, 2617, 2515, 2088, 1982, 1600, 1570, 1437, 1402, 1200, 1060, 988, 912, 808.
1 H-NMR (DMSO-d 6 9.0 (dd, 1H, Ar-H), 8.8 (dd, 1H, Ar-H), 8.3 (dd, 1H, Ar- 7.7 (ddd, 1H, Ar-H), 4.41 2H, -0CH 2 3.41-1.37 12H), 1.8 (quintet, 2H, -OCH 2
CH
2 CH) ppm.
13C-NMR (DMSO-d6): 148.5 Ar), 144.7 Ar), 136.4 Ar), 133.5 C- Cl), 128.6 Ar), 124.2 Ar), 72.5 OCH 2 52.4 CH 2 51.4 (t,
N-CH
2
-CH
2
-CH
2
-CH
2
-CH
2 22.6 0-CH 2
-CH
2
-CH
2 21.6 N-CH 2
CH
2
-CH
2 -CH2), 20.8 N-CH 2
-CH
2
-CH
2
-CH
2
-CH
2 ppm.
The above starting material can be prepared as follows: After dissolving 2.86 g (51.06 mmoles) of potassium hydroxide in 20 ml of abs. ethanol, 6.45 g (47.0 mmoles) of 3-pyridirecarboxamide oxime are portionwise added while stirring. After dissolution, 7.7 g (47.66 mmoles) of 1-(3chloropropyl)piperidine dissolved in 5 ml of ethanol are dropwise added. After 9hour reaction, the precipitated potassium chloride is filtered off, the ethanolic solution is clarified by activated carbon and evaporated. After taking up in 100 ml of chloroform, the evaporation residue is washed 3 times with 100 ml of 1 N sodium hydroxide solution each, then with 50 ml of water. After separation, the organic phase is dried over sodium sulfate, filtered and evaporated. The oily residue becomes crystalline on cooling. The crystals are triturated with about 20 ml of ether, filtered and dried to give a beige product in a yield of 4.8 g IR KBr y cm- 1 3422, 3107, 2937, 2870, 2819, 1640, 1479, 1391, 1309, 1194, WO 95/30649 PCT/HU95/00014 -11- 1123, 1059, 1042, 982, 916.
1 H-NMR (DMSO-d6): 8.85 (dd, 1H, J1=1,8 Hz, J2=0.8 Hz, Ar 8.58 (dd, 1H, Ar(6)H), 8.01 (dt, 1H, Ar(4)H), 7.40 (ddd, 1H, Ar(5)H), 6.16 (broad, 2H, NH2), 4.00 2H, J=6.6 Hz, OCH2), 2.43 2H, overlapped,
OCH
2 CH2N), 2.33 4H, -N-CH 2
CH
2
CH
2
CH
2
CH
2 1.77 (quintet, 2H, OCH2CH2CH2), 1.48 4H, -N-CH 2
CH
2
CH
2
CH
2 1.40 2H,
-N-CH
2 CH2CH2CH 2 CH2) ppm.
13 C-NMR (DMSO-d6): 149.9 Ar), 149.0 C-NH 2 146.6 Ar), 133.1 (d, Ar), 128.3 Ar), 123.1 Ar), 49.9 OCH2), 55.3 OCH 2
CH
2
CH
2 to 53.9 OCH 2 CH2CH 2
-N-CH
2 26.1 OCH 2
CH
2 25.4 -N-CH2-
CH
2
CH
2
CH
2
CH
2 24.0 -N-CH 2
CH
2
CH
2
CH
2 ppm.
B) 5.49 g (0.04 moles) of nicotinic acid amidoxime (Beilstein E III/V 22 page 439) are added under stirring to a solution containing 2.24 g (0.04 moles of potassium hydroxide in 30 ml of ethanol while stirring and, after complete dissolution, 3.93 ml (6.3 g, 0.04 moles) of 1-chloro-3-bromopropane are dropwise added during 15 minutes. After boiling the reaction mixture under reflux for 6 hours and then cooling down, the inorganic salt precipitated is filtered off and the solution is evaporated under reduced pressure. The residue is dissolved in 100 ml of chloroform, washed with 50 ml of 2 N sodium hydroxide solution, then 50 ml of water, oried over sodium sulfate and evaporated.
The oily residue is dissolved at -5°C in a mixture of 80 ml of distilled water and 23 ml of 37% hydrochloric acid. To this solution 13.79 g (0.2 moles) of sodium nitrite dissolved in 60 ml of water are dropwise added at the same temperature, then the reaction mixture is stirred at -50C for additional 2 hours. Subsequently, 150 ml of chloroform and 200 ml of sodium hydroxide solution are added and it is extracted. The organic phase is washed with 50 ml of water, dried over sodium sulfate and evaporated.
The obtained compound of formula (VII) [wherein Z 3-pyridinyl, WO 95/30649 PCT/HU95/00014 -12- Y=X=Cl and A=(CH 2 is dissolved in 100 ml of benzene, cooled to -10 0 C and 7.91 ml (6.81 g, 0.08 moles) of piperidine are dropwise added under stirring.
After boiling the mixture under reflux for 8 hours, then cooling down, the solid piperidine hydrochloride precipitate is filtered off and thoroughly washed with benzene. The filtrate is twice extracted with 200 ml of 3 N aqueous hydrochloric acid solution each. The combined aqueous phase is made alkaline upto pH 10 by adding 4 N sodium hydroxide solution, then extracted twice with 150 ml of chloroform each. The combined chloroformic phase is dried over sodium sulfate, filtered and evaporated.
The brown oily residue is purified by column chromatography (Merck Kieselgel 60, eluent: chloroform/methanol 1:1) to obtain 4.81 g of base which is converted to the dihydrochloride salt as described in Example 3A.
Example 3 Preparation of N-methoxy-3-pyridinecarboximldoyl chloride hydrochloride A) A solution containing 2.5 g (13.3 mmoles) of N-methoxy-3-pyridinecarboxamidine hydrochloride in the mixture of 3.7 ml of concentrated hydrochloric acid and 36 ml of water is cooled to 5 0 C, then a solution of 1.14 g (16. 4 mmoles) of sodium nitrite in 6.5 ml of water is dropwise added and stirred at the same temperature for additional 30 minutes.
After layering 30 ml of chloroform to the mixture and then adjusting the pH-value to 8-9 by adding solid sodium carbonate, the chloroformic phase is separated, the aqueous layer is again extracted with 30 ml of chloroform, then the combined chloroformic solution is washed with 10 ml of saturated saline solution, dried over sodium sulfate and evaporated.
The obtained residue weighing 1.9 g is dissolved in 10 ml of isopropanol and 5.2 ml of 2.1 molar solution of hydrogen chloride in isopropanol are added to obtain the hydrochloride salt in title in a yield of 1.06 g 136-139 0
C.
1 H-NMR (DMSO): 11.5 (broad, 1H, 9.06 1H), 8.91 (dd, 1H), 8.59 (m, WO 95/30649 PCT/HU95/00014 13- 1H), 7.93 (dd, 1H pyridine 4.1 3H, CH 3 ppm.
1 3 C-NMR (DMSO): 145.7, 142.1, 139,7, 129.8, 126.0 (pyridine 2-6-4-3-5), 132.2 63.5 (CH 3 ppm.
The above starting material is prepared as follows: The mixture containing 6.85 g (0.05 mmoles) of 3-pyridinecarboxamidoxime, 3,37 g (0.06 moles) of potassium hydroxide, 3.15 ml (7.18 g, 0,051 moles) of methyl iodide and 100 ml of ethanol is stirred at room temperature for 3 hours. After evaporation, the residue is dissolved in 100 ml of water, extracted 3 times with 100 ml of ethyl acetate each, the combined organic phase is washed io with 100 ml of 1 N sodium hydroxide solution, then twice with 50 ml of saturated saline solution each, dried over sodium sulfate and evaporated.
The obtained residue (3.5 g) is dissolved in 50 ml of ether, clarified with activated carbon and again evaporated to obtain 3.14 g of solid product, 49-56 0
C.
After dissolving the crude product in 30 ml of isopropanol, 9.8 ml of 2.1 molar solution of hydrogen chloride in isopropanol are added to obtain the hydrochloride, which is then crystallized to give 3.38 g of the aimed hydrochloride, 158-164°C (recrystallized from methanol/ether).
B) Gaseous chlorine is introduced in a slow flow for 30 minutes to the solution of 2.72 g (20 mmoles) of 0-methyl-nicotinealdoxime dissolved in 30 ml of chloroform. After evaporating the mixture to dryness, the residue is recrystallized from isopropanol to give the title hydrochloride in a yield of 2.4 g the physical characteristics of which are identical to those prepared by method A).
Example 4 Preparation of 0-(3-diethylaminopropyl)-3-pyridinehydroximoyl chloride hydrochloride g (37.9 mmoles) of N-(3-diethylaminoprop3xy)-3-pyridinecarboxamidine are added under stirring to the mixture of 65 ml of distilled water and 21.7 ml of concentrated hydrochloric acid, cooled to 0°C. To the yellow solution I- WO 95/30649 PCT/HU95/00014 -14- 13.08 g (189.5 mmoles) of sodium nitrite dissolved in 54 ml of distilled water are dropwise added at -5 0 C during 50 minutes, then the reaction mixture is stirred at a temperature of -5 0 C for 2 hours. Subsequently, the pH of the solution is adjusted to 11 by adding 2 N sodium hydroxide solution and the mixture is extracted 3 times with 70 ml of chloroform each. The organic phase is washed with ml of water, dried over sodium s:lfate and evaporated. The residue is purified by column chromatography (adsorbent: Merck Kieselgel 60; eluent: chloroform/methanol The base obtained in a yield of 5.17 g is transformed by adding methanolic solution of hydrogen chloride to obtain the title hydrochloride, 152-153 0
C.
IR (KBr) y cm- 1 3044, 2937, 2752, 2533, 2658, 2492, 1587, 1477, 1416, 1055, 1022, 976, f397, 816, 704.
1 H-NMR (DMSO-d6): 11.1 (broad, 1H), 9.0 (dd, 1H, Ar-H), 8.7 (dd, 1H, Ar-H J1=5.3 Hz, J2=1.5Hz), 8.18 (dt, 1H, Ar-H, J=8.7 Hz, J 2
=J
3 =1.5 Hz), 7.53 (dd, 1H, Ar-H), 4.45 2H, J=6.2 Hz, OCH 2 3.1 2H, CH 2
CH
2 3.1 2H, CH 2
CH
3 2.2 2H, OCH 2 -CH2 1.23 3H, J=7.2 Hz, CH3) ppm.
13C-NM (DMSO-d6): 151.4 Ar), 147.1 Ar), 134.6 C-C1), 134.4 (d, Ar), 127.2 Ar), 123.6 Ar), 72.2 OCH2), 46.7 CH 2 45.8 (t,
N-CH
2
-CH
3 22.5 CH 2
-CH
2
-CH
2 8.1 CH 3 ppm.
Example Preparation of 0-(3-morpholinopropyl)-3-pyridinehydroximoyl chloride dihydrochloride g (9.45 mmoles) of N-(3-morpholinopropoxy)-3-pyridinecarboxamidine are added to the mixture of 15 ml of distilled water and 5.41 ml of concentrated hydrochloric acid cooled to OC under stirring. To the yellow solution 3.26 g (47.25 mmoles) of sodium nitrite dissolved in 15 ml of water are dropwise added at a temperature of -5 0 C during 30 minutes. The reaction mixture is stirred at WO 95/30649 PCT/HU95/00014 0 C for 2 hours. Then, the pH of the solution is adjusted to 11 by addirg 2 N sodium hydroxide solution and it is extracted 3 times with 5 ml of chloroform each. The organic phase is washed with 30 ml of water, dried over sodium sulfate and evaporated. An ethereal solution of hydrogen chloride is added to the evaporation residue until reaching pH=2 value to obtain 2.42 g of the title dihydrochloride, 196-200 0
C.
IR (KBr) y cm-1: 3017, 2483, 2095, 1630, 1574, 1551, 1480, 1350, 1281, 1111, 1083, 980, 808, 714, 675.
1 H-NMR (DMSO-d 6 11.4 (broad, 1H), 11.15 (broad, 1H), 9.12 1H, Hz), 8.92 (dd, 1H, J1=5.3 Hz, J2=5.3 Hz) 8.60 (dt, 1H, J=8.7 Hz, J2=J3=1,5 Hz). 7.91 (dd. 1H, J1=8.7 Hz, J 2 =5.3 Hz), 4.44 2H, OCH2), 3.9 4H, N-CH2-CH2-0), 3.44 2H, J=12.2 Hz, N-CH 2
-CH
2 equ), 3.3-3.0 2H, N-CH2-CH2-0, 3.3-3.0 2H, CH 2
-CH
2 2.3 (m, 2H, CH 2 -CH2-CH 2 ppm.
13 C-NMR (DMSO-d 6 146.6 Ar), 143.0 Ar), 139.3 Ar), 133.3 (C-C1), 129.7 Ar), 125.7 Ar), 72.8 OCH 2 62.9 N-CH 2
-CH
2 52.6
CH
2
-CH
2 50.7 N-CH 2
-CH
2 22.6 0-CH 2
-CH
2
-CH
2
-N)
ppm.
Elementar analysis for C1 3 H18N 3 0 2 .2HCl: calculated: C 43.8; H 5.65; N 11.78%; found: C 44.4; H 5.7; N 11.9%.
The above starting substance is prepared as follows: To the solution of 5.72 g (0.102 moles) of potassium hydroxide in 40 ml of ethanol 12.89 g (0.094 moles) of 3-pyridinealdoxime are added under stirring, then, after dissolution, 15.6 g (0.0953 moles) of 1-(3-chloropropyl)morpholine dissolved in 10 ml of ethanol are dropwise added to the reaction mixture, which is boiled under reflux for 9 hours. The precipitated potassium chloride is filtered off, the filtrate is clarified by using activated carbon and evaporated. After disso- WO 95/30649 PCT/HU95/00014 -16lution of the residue in 200 ml of chloroform, the solution is washed 3 times with 100 ml of 1 N sodium hydroxide solution each, then 3 times with 100 ml of water each. After drying the organic phase over sodium sulfate and filtering, the filtrate is evaporated. The residue is purified by column chromatography (adsorbent: Merck Kieselgel 60; eluent: chloroform/methanol The purified base is crystallized from ether to obtain a yield of 3.6 g 61-63 0
C.
1 H-NMR (DMSO-d 6 8.85 1H, J=1.5 Hz, Ar), 8.62 (dd, 1H, J 1 =5.3 Hz,
J
2 =1.5 Hz, Ar), 7.94 (dt, 1H, J=8.7 Hz, J 2
=J
3 =1.5 Hz, Ar), 7.31 (dd, 1H,
J
1 =8.7 Hz, J 2 =5.3 Hz, Ar), 4.96 (broad s, 2H, NH.2), 4.16 2H, J=6.5 Hz,
=N-O-CH
2 3.70 4H, N-CH 2 -CH2-O), 2.48 2H, J=6.5 Hz, overlapped, N-O-CH 2
-CH
2
-CH
2 2.47 4H, -N-CH 2
-CH
2 1.92 (m, 2H, O-CH 2 -CH2-CH 2 ppm.
13 C-NMR (DMSO-d6): 150.7 Ar), 149.35 C-NH 2 147.0 Ar), 133.4 Ar), 128.5 Ar), 123.3 Ar), 72.0 =N-O-CH 2 66.9) t, N-CH 2
CH
2 55.8 -O-CH 2
-CH
2 53.7 N-CH 2
-CH
2 26.3 N-O-
CH
2 -CH2) ppm.
Example 6 Preparation of 0-( 2 -piperidinoethyl)-3-pyridinehydroximoyl chloride hydrochloride 2.6 g (10.47 mmoles) of N-(2-piperidinoethoxy)-3-pyridinecarboxamidine are added under stirring to the mixture of 17 ml of distilled water and 6 ml of concentrated hydrochloric acid, cooled to 0°C. Then, 3.62 g (52.45 mmoles) of sodium nitrite dissolved in 15 ml of distilled water are dropwise added at during 30 minutes. After adjusting the pH value to 11 by adding 2 N sodium hydroxide solution, the mixture is extracted 3 times with 50 ml of chloroform each.
The organic phase is washed with 30 ml of water, dried over sodium sulfate and evaporated. The evaporation residue weighing 1.38 g (49.23%) is transformed to the title hydrochloride salt, 149-150 0 C (crystallized from ether) by adding
I
WO 95/30649 PCT/HU95/00014 -17metbanolic hydrogen chloride solution.
IR (KBr) y cm-1: 3433, 2945, 2633, 2540, 1587, 1450, 1414, 1271, 1059, 1038, 1007, 954, 920, 822, 706.
1 H-NMR (DMSO-d6): 11.12 (broad s, 1H), 9.03 1H, J=1.5 Hz, Ar), 8.72 (dd, 1H, J1=5.3 Hz, J2=1.5 Hz), 8.20 (dt, J=8.7 Hz, J 2
=J
3 =1.5 Hz, Ar), 7.52 (dd, 1H, J 1 =8.7 Hz, J 2 =5.3 Hz, Ar), 4.38 J=5.0 Hz, OCH2), 3.48 (t, Hz, overlapped CH 2 -CH2-N), 3.5-3.0 4H, N-CH2-CH 2
CH
2 2.0-1.6 4H, N-CH 2
-CH
2 CH2), 1.20 ax., H, N-CH 2
CH
2 CH2) ppm.
13 C-NMR (DMSO-d 6 151.6 Ar), 147.3 Ar), 135.8 C-CI), 134.5 (d, Ar), 127.6 Ar), 123.6 Ar), 69.7 OCH 2 53.9 CH 2
-CH
2 52.2
N-CH
2
-CH
2
CH
2 22.0 N-CH2-CH2CH2), 20.9 N-CH 2 -CH2CH 2 ppm.
Elementar analysis for C 13
H
18
N
3 0C1.HC
I
calculated: C 51.33; H 6.30; N 13,81%; found: C 51.4; H 6.3; N 13.8%.
The above starting substance is prepared as follows: After dissolving 6.45 g (47.0 mmoles) of 3-pyridinecarboxamidine in 120.4 ml of 0.83 N potassium hydroxide solution in ethanol under stirring, 8.65 g (47.0 mmoles) of 1-(2-chloroethyl)piperidine hydrochloride are added under stirring, then the reaction mixture is boiled under reflux for 4 hours. The precipitated potassium chloride is filtered off, the filtrate is clarified by activated carbon and evaporated. The residue is dissolved in 100 ml of chloroform and the organic solution is washed 3 times with 100 ml of 1 N sodium hydroxide solution each, then with 50 ml of water. The organic phase is dried over sodium sulfate and evaporated. The residue is purified by column chromatography (adsorbent: Merck Kieselgel 60; eluent: chloroform/methanol The purified product is recrystallized from ether to give 2.69 g of the aimed product, m. 81- 83 0 C. (from ether).
-18- 1 H-NMR (DMSO-d 6 8.86 1H, J=i.5 Hz, Ar), 8.60 (dd, 1H, J1-5.3 Hz, J2=1.5 Hz, Ar), 7.93 (dt, 1H, J=8.7 Hz, J 2 =J3=1.5 Hz, Ar), 7.28 (dd, 1H,
J
1 =8.7 Hz, J 2 =5.3 Hz, Ar), 5.16 (broad s, 2H, NH 2 4.23 2H, J=5.9 Hz,
=N-O-CH
2 2.70 2H, J=5.9 Hz, O-CH2-CH2-N), 2.48 4H, N-CH2-
CH
2
-CH
2 1.57 4H, -N-CH 2
-CH
2
-CH
2 1.43 2H, N-CH 2
-CH
2
CH
2 ppm.
13 C-NMR (DMSO-d 6 150.6 Ar), 149.8 C-NH 2 147.1 Ar), 133,4 (d, Ar), 128.6 Ar), 123.2 Ar), 71.3 =N-O-CH2), 54.9 -O-CH 2
-CH
2
-N-CH
2 25.8 -N-CH 2
-CH
2 24.15 -N-CH 2
-CH
2
.CH
2 10 ppm.
S: Example 7 Preparation of 0-(3-piperidinopropyl)-3-nitro-benzhydroximoyl chloride hydrochloride 3.22 g (10.5 mmoles) of N-(3-piperidinopropoxy)-3-nitrobenzamidine are added under stirring to a mixture of 15 ml of distilled water and 15 ml of concentrated hydrochloric acid, cooled to 0°C. Then, 3.62 g (52.05 mmoles) of sodium nitrite dissolved in 10 ml of water are dropwise added to the reaction mixture at -5'C during 30 minutes. The pH value of the solution is adjusted to 10 by adding 2 N sodium hydroxide solution, then it is extracted 3 times with 50 ml of chloro- 20 form each. The organic phase is washed with 30 ml of water, dried over sodium sulfate and evaporated. The evaporation residue is purified by column chromatography (adsorbent: Merck Kieselgel 60; eluent: chloroform/methanol The obtained base weighing 1.7 g is transformed to the title hydrochloride by adding an ethereal solution of hydrogen chloride, 173-175 0
C.
IR (KBr) y cm- 1 3420, 2926, 2953, 2649, 2546, 1614, 1591, 1533, 1452, 1354, 1295, 1252, 1049, 994, 733.
1 H-NMR (DMSO-d 6 10.75 (broad 8.51 Jl=J 2 =1.9 Hz, Ar), 8.40, 8.25 •v 7-- I II I WO 95/30649 PCT/HU95/00014 -19- (dd, 2H, J1=8.1 Hz, J 2 =1.9 Hz), 7.81 J 1 =J2=8.1 Hz), 4.44 J=6.2 Hz), 3.45 2H, CH 2
NCH
2 3.15 2H, CH 2
NCH
2 2.85 2H, CH2-
NCH
2 2.25 2H, OCH 2 CH2CH 2 2.0-1.6 5H), 1.4 1H, N-
CH
2
CH
2
CH
2
CH
2
CH
2 ppm.
13 C-NMR (DMSO-d 6 147.1 Ar), 134.9, 132.9 C-C1), 134.9 Ar), 132.7, 130.5 Ar), 125.3 Ar), 121.0 Ar), 72.7 0CH 2 52.6 (t,
CH
2 51.6 N-CH 2
CH
2
CH
2
CH
2
CH
2 22.9, 21.2 OCH 2
CH
2 22.9, 21.2 N-CH2CH 2
CH
2 CH2 2 and OCH 2
-CH
2 22.0 N-
-CH
2
CH
2
CH
2
CH
2
CH
2 ppm.
Example 8 Preparation of N-[3-(1-piperidinyl)propoxyj-3'-(trifluoromethyl)benzimidoyl chloride hydrochloride To a solution containing 4 g (11.0 mmoles) of N-[3-(1-piperidinyl)propoxy]-3'-(trifluoromethyl)benzamidine hydrochloride in the mixture of ml of distilled water and 10 ml of concentrated hydrochloric acid 2.07 ml of aqueous sodium nitrite solution are dropwise added at a temperature of -5 0 C under stirring. The reaction mixture is stirred at -5 0 C and then 3 times an additional amount 1 ml of the above sodium nitrite solution each is added every 2 hours.
After additional stirring for 4 hours, the excess of the reagent is decomposed with urea, then the solution is diluted with 35 ml of water and extracted twice with ml of ether each. The aqueous phase is alkalinized by adding 4 N sodium hydroxide solution and extracted 3 times with 40 ml of ethyl acetate each. The organic phase is washed 3 times with 20 ml of water each, 4 times with 30 ml of buffer solution (pH=5) each, then washed with 20 ml of saturated saline solution, dried over sodium sulfate and evaporated. The residue is transformed by adding a methanolic solution of hydrogen chloride to obtain the title compound in a yield of 2.56 g 124-129 0 C (from ethyl acetate).
IR (KBr)y cm- 1 3425 (broad), 2941, 2648, 2548, 1333, 1244, 1165, 1123, 1072, I II II WO 95/30649 PCTIHU95/00014 995, 984, 802, 709, 698.
1 H-NMR (DMSO-d6): 11.0 (1H, broad, NH), 8.13 (1H, d, J=8.0 Hz), 8.05 (1H, 7.92 1H, J=8 Hz), 7,76 1H, J=8 Hz), Ar), 4.40 2H, J=6 Hz),
OCH
2 3.50-3.35 2H), 3.2-3.0 2H), 2.95-2.75 2H, 3xNCH 2 2.35-2,15 2H, CH 2 2.0-1.6 5H), 1.5-1.25 1H, 3xCH2/piperidine) ppm.
13 C-NMR (DMSO-d6): 135.4 132.5, 130.7, 130.1, 129.4 J=32 Hz), 127.4 J=3.5 Hz), 122.8 J=3,8 Hz, Ar), 123.5 J=270,8 Hz, CF3), 72.6 (OCH 2 52.7, 51.6 (2xNCH2), 22.9, 22.0, 21.2 (3xCH 2 ppm.
Elementar analysis for C 16
H
20
N
2 0F 3 C1. HCI: calculated: C 49.88; H 5.49; N 7.27%; found: C 49.8; H 5.6; N 7.6%.
The above starting substance can be prepared as follows: A solution containing 8.0 g (40 mmoles) of 3-(trifluoromethyl)benzamidoxime, 4.68 g (29.0 mmoles) of N-(3-chloropropyl)piperidine and 1.68 g (29.8 mmoles) of potassium hydroxide in 100 ml of ethanol is boiled under reflux for hours. After filtering off the potassium chloride precipitated, the filtrate is evaporated to dryness under reduced pressure. The residue is recrystallized from water, filtered, washed with water and dried. The crude base obtained in a yield of 11.1 g 53-62 0 C, is dissolved in 22 ml of ethyl acetate and acidified with 7.8 ml of 4.3 molar methanolic hydrogen chloride solution. After evaporation, the product is recrystallized from pure ethyl acetate to give 6.1 g of the aimed product.
(IR KBr) y cm1l: 3412, 3082 (broad), 2949, 1655, 1325, 1171, 1121, 1072, 986, 920, 905, 808, 700.
1 H-NMR (DMSO-d6): 8.00 1H), 7.98 1H, J=8.0 Hz), 7,75 1H, Hz), 7.62 1H, J=8.0 Hz, Ar), 6.23 2H, NH 2 3.98 2H, J=6 Hz,
OCH
2 2.45-2.25 6H, 3xNCH 2 1.79 (quintet, 2H, J=7 Hz, CH 2 1.6- WO 95/30649 PCT/HU95/00014 -21- 1.3 6H, 3xCH2/piperidine) ppm.
13 C-NMR (DMSO-d 6 149.6 [C(NH 2 133.4, 129.5, 129.1, 128.8 (q, J=32 Hz), 125.5 J=3.5 Hz) and 121.9 J=3.8 Hz, Ar), 123.9 (q, J=270.8 Hz, CF 3 70.8 (OCH 2 55.1, 53.8 (2xnCH 2 26.0, 25.3, 23.9 (3xCH2) ppm.
Elementar analysis for C 16
H
2 2 N30F 3 HC1: calculated: C 52.53; H 6.34; N 11.49%; found: C52.1; H6.3; N 11.2%.
Example 9 1o Preparation of N-[3-(4-methylpiperazin-1-yl)-l-propoxy]-3-pyridinecarboximidoyl chloride trihydrochloride g (5.4 mmoles) of N-[3-(4-methylpiperazin-1-yl)-l-propoxy]-3-pyridinecarboxamidine are added under stirring to a mixture containing 10 ml of distilled water and 10 ml of concentrated hydrochloric acid, cooled to 0°C. To the yellow solution 1.86 g (0.027 moles) of sodium nitrite di, olved in 5 ml of distilled water are dropwise added at -5°C temperature during 30 minutes. After stirring the reaction mixture at -5°C for 1.5 hours, the pH value of the solution is adjusted to 10 by adding 2 N sodium hydroxide solution and extracted 3 times with 50 ml of chloroform each. The organic phase is washed with 30 ml of water, dried over sodium sulfate and evaporated. After dissolving the residue in ethyl acetate, the title compound is precipitated by adding ethereal hydrogen chloride solution until pH 2. The precipitate is filtered, washed with ether and recrystallized from 80 ml of ethanol after clarifying with activated carbon to obtain the title trihydrochloride in a yield of 1.0 1 H-NMR (DMSO-d6): 9.06 1H, J=1.6 Hz, Ar), 8.80 1H, J=4.9 Hz, Ar), 8.36 (dt, 1H, J 1 =8.2 Hz, J2=J3=1.6 Hz, Ar), 7.72 (dd, 1H, J 1 =8.2 Hz,
J
2 =4.9 Hz, Ar), 4.43 2H, 7=6.3 Hz, OCH 2 3.65 (broad, 8H,
NCH
2
CH
2 3.3 2H, J=7.8 Hz, CH 2
CH
2
CH
2 2.84 3H, CH 3 2.30 WO 95/30649 PCT/HU95/00014 -22- 2H, CH 2
CH
2 CHI) ppm.
13 C-NMR (DMSO-d6): 149.0 Ar), 145.01 Ar), 136.9 Ar), 133.9 (s, 128.7 Ar) 124.7 Ar), 72.4 OCH 2 52.4 CH 2 49.2, 47.8 (t -N-CH2-CH2N), 41.7 N-CH 3 22.9 CH 2
CH
2
CH
2 ppm.
The above starting substance can be prepared as follows: 2.74 g (0.02 moles) of 3-pyridinealdoxime are added to the solution of 1.24 g (0.022 moles) of potassium hydroxide in 30 ml of ethanol. After dissolution, 3.15 g (0.02 moles) of N-methyl-N'-(3-chloropropyl)piperazine dissolved in ml of ethanol are dropwise added to the reaction mixture during about 10 mino1 utes. The mixture is boiled under reflux for 11.5 hours while stirring. The precipitated potassium chloride is filtered off, the filtrate is clarified by the means of activated carbon and Celite® filtering aid and then evaporated in a rotavapor equipment. The residue is dissolved in 100 ml of chloroform, washed twice with ml of 2 N sodium hydroxide solution each, then with 30 ml of water, the organic phase is dried over sodium sulfate and evaporated. The residue is purified by column chromatography (adsorbent: Merck Kieselgel 60; eluent: a mixture of chloroform, methanol and concentrated ammonium hydroxide in a ratio of 30:5:0.2) to obtain 1.72 g of product.
IR y cm- 1 3387, 2947, 2802, 1730, 1639, 1450, 1389, 1283, 1242, 1194, 1150, 1083, 814, 710.
1 H-NMR (DMSO-d6): 8.85 1H, J=2.0 Hz, Ar), 8.61 (dd, 1H, J1=4.9 Hz, J2=2.0 Hz, Ar), 7.95 (dt, 1H, J1=7.7 Hz, J 2 =J3=2.0 Hz, Ar), 7.29 (dd, 1H,
J
1 =7.7 Hz, J2=4.9 Hz, Ar), 5.1 (bs, 2H, NH2), 4.15 2H, J=6,4 Hz,
OCH
2 2.5 10H, J=5.9 Hz, -OCH 2
-CH
2
CH
2 2xNCH 2
-CH
2 2.27 3H, (CH3), 1.95 2H, -CH 2
-CH
2
CH
2 ppm.
13 C-NMR (DMSO-d6): 150.5 Ar), 149.3 146.9 Ar), 133.3 (d, Ar), 128.5 Ar), 123.1 Ar), 72.0 OCH 2 55.2 OCH 2 CH2CH 2 WO 95/30649 PCT/HU95/00014 -23 54.9 2xNCH 2 CH2N), 53.0 2xNCH2CH2N), 45.9 N-CH3), 26.5 (t,
-OCH
2
-CH
2 CH2) ppm.
Example Preparation of 0-(2,2-dimethyl-3-piperidinopropyl)-3-pyridinecarbohydroximoyl chloride To a solution containing 2.23 g (7 63 mmoles) of N-(2,2-dimethyl-3-piperidinopropoxy)-3-pyridinecarboxamidine in 30 ml of a 1:1 mixture of concentrated hydrochloric acid and water 2.63 g (38.2 mmoles) of sodium nitrite dissolved in ml of water are dropwise added at 0°C. The reaction mixture is stirred at the 0o same temperature for additional 2 hours, then the pH value is adjusted to 12 by adding 2N sodium hydroxide solution and the mixture is extracted twice with ml of chloroform each. The organic phase is washed with 30 ml of water, dried over sodium sulfate, filtered and evaporated. The oily residue (1.83 g) is purified by column chromatography to give the title compound as a pale yellow oil in a yield of 1.62 g IR (KBr) y cm-l: 3433, 2934, 2783, 1583, 1475, 1416, 1271, 1157, 1113, 1055, 1034, 1003, 914, 860, 806, 704.
1 H-NMR (CDCl 3 9.06 (1H, dd, J1=2.4 Hz, J 2 =1.0 Hz, pyridine 8.61 (1H, dd, J1=4.8 Hz), J2=1.7 Hz, pyridine 6H), 8.08 (1H, ddd, 11=8.1 Hz,
J
2 =2.4 Hz, J 3 =1.7 Hz, pyridine 7.30 (1H, ddd, J 1 =8.1 Hz, J2=4.8 Hz,
J
3 =1.0 Hz, pyridine 5H), 4.14 (2H, s, OCH2), 2.46 (4H, t, J=4.9 Hz, piperidine), 2.18 (2H, s, CH 2 1.55 (4H, m, piperidine), 1.37 (2H, m, piperidine), 0.94 (6H, s, CH 3 ppm.
The above starting material is prepared as follows: 2.74 g (0.02 moles) of pyridine-3-amidoxime are added under stirring to a solution of 2.46 g (0.044 moles) of potassium hydroxide in 40 ml of abs. ethanol under stirring. After dissolution, 4.52 g (0.02 moles) of (1-(2,2-dimethyl-3chloropropyl)-piperidine hydrochloride are portionwise added, then additional WO 95/30649 PCT/HU95/00014 -24ml of ethanol are added. After boiling the heterogeneous mixture under reflux for 11 hours, the solid precipitate is filtered off, washed with ethanol and the solution is evaporated. After adding 100 ml of chloroform to the residue, the solution is washed twice with 100 ml of 2 N sodium hydroxide solution each, then 50 ml of water. The organic phase is dried over sodium sulfate, filtered and the solution obtained is evaporated. The oily brown residue is purified by column chromatography to give the pale yellow oily product in a yield of 2.23 g IR (KBr) y cm- 1 3323, 2935, 2866, 2785, 1637, 1477, 1393, 1157, 111, 1057, 995, 943, 814, 708.
to 1 H-NMR (CDC1 3 8.87 (1H, dd, J 1 =2.2 Hz, J 2 =0.7 Hz, pyridine-2H), 8.60 (1H, dd, J 1 =4.8 Hz, J 2 =1.7 Hz, pyridine-6-H), 7.93 (1H, ddd, Ji=8.1 Hz, J 2 =2.2 Hz, J 3 =1.7 Hz, pyridine-4-H), 7.30 (1H, ddd, Ji=8.1 Hz, J 2 =4.8 Hz, J3=0.7 Hz, pyridine-5-H), 4.89 (2H, bs, NH 2 391 (2H, s, OCH 2 2.48 (4H, t, J=4.8 Hz, piperidine), 2.17 (2H, s, CCH 2 1.55 (4H, m, piperidine), 1.44 is (2H, m, piperidine), 0.95 (6H, s, CH 3 ppm.
Claims (8)
1. Compounds of the formula X S- C N OR wherein X means halogen; Z stands for an aromatic group, pyridinyl group or its homologues; and R represents an alkyl or phenylalkyl group or an -A-N(R 1 )R 2 group, and in the latter R 1 and R2 stand, independently from each other, for hydrogen or alkyl group; or R 1 and R 2 together with the adjacent nitrogen atom, 15 form a 5- to 7-membered, saturated heterocyclic group optionally containing an additional nitrogen, oxygen or sulfur atom, said heterocylic group optionally being substituted by at least one alkyl group; and A stands for a straight or branched chain alkylene group as well as pharmaceutically acceptable acid addition salts thereof.
2. Compounds of formula according to claim 1, wherein Z as aromatic group stands for phenyl, phenylalkyl, substituted phenyl, substituted phenylalkyl or naphthyl group, said substituted phenyl group optionally being substituted by 1 to 3 identical or different group(s), which may be halogen, haloalkyl, alkyl, hy- droxy, alkoxy, nitro, amino, monoalkylamino or dialkylamino group.
3. Compounds of formula according to claim 1, wherein Z stands for pyridinyl or a homologue thereof.
4. Compounds of formula according to claim 3, wherein Z means a 3- pyridinyl group. ~%R~A~9~03~PHII1 rarrmur~ -26- Compounds of formula according to any of the claims 1 to 4, wherein R represents an -A-N(R 1 )R 2 group, where R 1 and R 2 together with the adjacent nitrogen form a piperidino, piperazino or morpholino group.
6. Compounds of formula according to any of the claims 1 to 5, wherein A means a Cl_ 5 alkylene group.
7. A pharmaceutical composition, which comprises as active ingredient a therapeutically effective amount of a compound of formula wherein X, Z and R are as defined in claim 1, or a pharmaceutically acceptable acid addition salt thereof, together with carriers and/or additives commonly used in the pharma- ceutical industry.
8. A process for the preparation of the compounds of formula X z- C SN-OR 15 wherein X means halogen; Z stands for an aromatic group, pyridinyl group or its homologues; and R represents an alkyl or phenylalkyl group or an -A-N(R 1 )R 2 group, and in the latter 20 R 1 and R 2 stand, independently from each other, for hydrogen or alkyl group; or R 1 and R 2 together with the adjacent nitrogen atom, form a 5- to 7-membered, saturated heterocyclic group optionally containing an additional nitrogen, oxygen or sulfur atom, said het- erocyclic group optionally being substituted by at least one alkyl 25 group; and A stands for a straight or branched chain alkylene group, as well as the pharmaceutically acceptable acid addition salts thereof, which comprises a) treating a compound of formula "X \h 0/-U1 "Vj WO 95/30649 PCT/HU95/00014 -27- NH 2 Z- C N-OR wherein Z and R are as defined above, or an acid addition salt thereof, with a di- azotizing agent in the presence of a hydrogen halide or b) reacting a compound of the formula X Z- C mi), N-OH o0 wherein X and Z are as defined above, with a compound of the formula R-Y (IV), wherein R is as defined above and Y means a leaving group, in the presence of an acid binding agent; or c) treating a compound of the formula 0 Z- C NH OR or a compound of formula Z-CH=NOR (VI), wherein Z and R are as defined above, with a halogenating agent; or d) reacting a compound of formula X Z- C (VII), N-O-A-Y wherein Z, X, Y and A are as defined above, with an amine of formula HN(R1)R2, where R 1 and R 2 are as defined above, to obtain a compound of formula wherein R means an -A-N(R 1 )R 2 group; and, if desired, converting the obtained product prepared according to any of the above processes c) or respectively, to a pharmaceutically acceptable WO 95/30649 WO 9530649PCT/HU95/00014 28 acid addition salt.
9. Method of treating isoheamnic states or diseases in mammals including men, characterized by administering to said mammal a therapeutically effective amount of a compound of formula wherein Z, X and R are as defined in claim 1, or a pharmaceutically acceptable acid addition salt thereof, alone or in the form of a pharmaceutical composition. A compound of formula NH 2 N- OR selected from the group consisting of' N-(3-piperidino-l1-propoxy)-3-pyridinecarboxamidine, N-methoxy-3-pyridinecarboxamidine, N-(3-morpholinopropoxy)-3-pyridinecarboxamidine, N-(2-piperidinoethoxy)-3-pyridinecarboxamidine, 1-piperidinyl)-propoxy]-3 '-(trifluoromethyl)benzamidine, N-(3-(4-methylpiperazin- 1-yl)l1-propoxy]-3-pyridinecarboxanmidine, N-(2,2-dimethyl-3-piperidinopropoxy)-3-pyridinecarboxanmidine as well as the acid addition salts of these compounds. INTERNATIONAL SEARCH REPORT International application No. PCT/HU 95/00014 A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C 07 C 259/02; C 07 D 213/78,295/088; A 61 K 31/15,31/455 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C 07 C 259/00; C 07 D 213/00,295/00; A 61 K 31/00 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Database DARC on Questel C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A EP 0 417 210 B1 (BIOREX KUTATO-FEJLESZTj KFT.) 1-4,7,8,10 09 March 1994 (09.03.94), claims 1,2; examples 1,3. A JP 60-8253 A (SHOWA DENKO 17 January 1985 1 (17.01.85), compounds no. 3-7 (cited in the application). A Chemical Abstracts, Vol.89, No.25, 18 December 1978 (Columbus, Ohio, USA), page 560, column 1, abstract No. 215038s, BELTRAO,T.M. et al. "Preparation and spectral study of 0-methylbenzamidoximes", An.Acad. Bras.Cienc.1978,50(2),159-64 (Port). Further documents are listed in the continuation of Box C. Sec patent family annex. Special categories of cited documents: laterdocumet publishedafter theinternational filingdateorpriority document defining the general stateof the art which is not considered date and no in confict with th application but cite to understand to be of particular relevance the principle or theory underlying the invention earlier document but published on or after the international filing date document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive document which may throw doubts on priority claim(s) or which is step hen the document is taken alo i cited to establish the publication date of another citation or other special reason (as specified) document of particular relevance; the claimed invention cannot be document referring to an oral disclosure, use, exhibition or other considered to involve an inventive step when the document is means combined with one or moreothersuch documents, such combination Means being obvious to a person skilled in the art P" document published prior to the international filing date but later thaning obvious to a person skilled in the art the priority date claimed document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 28 June 1995 (28.06.95) 21 July 1995 (21.07.95) Name and mailing address of the ISA/ AT Authorized officer AUSTRIAN PATENT OFFICE Kohlmarkt 8-10 Kirber e.h. A-1014 Vienna Facsimile No. 1/53424/535 Telephone No. 1/5337058/28 Form PCT/ISA/210 (second sheet) (July 1992) ITERNATIONAL SEARCH REPORT Iniformation an patent family members intemnational application No. PCT/HU 95/00014 Im Recherchenbericht Datum der Ilitn lied(er) der Datum der angefahrtes Patentdokument Verfiffentlichung Pa entfamilie Verliffentlichung Patent document cited Publication Patent family Publication in search report date member Cs) date Document de brevet cit6 Date de Membre(s) de la Date de dans le rapport de recherche publication famille de brevets publication F" D.1 4172 09-03-94. AT E 10 26 03 15 94 AU Al1 44196 '/29 14-05--90 AU B 2 620460 C)2'9 CA AA 2 0C)08 30 20-C1496 D E COD 689 13-737 14 4 9L, DE T2 68913737 28-07-94. D K A 149-7/90.- 111-0690 QK A C) 1497/90 19-06-90 EP Al1 417210 2 0 9 1 E S AF 20200:30 /93 9 030'o7 5 1 06 4 F1 13 932 4 30-11-911 CGfi A B9100t66 9 291190 HU A2 54110 2~8-01-91 HU B 20798e 28-07-93 1IL AC)i 92C00 12 -07-90 1 L Al1 9200C 24-06-94 JP' -2 3 50 29 .1 04-07-91 NO0 A 902703. 18-o6-90 114 AO 0 207 1'8-06-90 FIT A 9,204 1 US A 5147879 .5-09-92 US A 5328906 12-07-94j WO Al 9004564 03-)o5-90 us A 5296606 22-03-9411 A 6085 Rii J Form PCM/SAI21O (patent family annex) (July 1992)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU9401488A HU219916B (en) | 1989-12-22 | 1994-05-06 | Hydroximic acid derivatives, process for producing them and pharmaceutical compositions containing them and certain intermediates |
HU9401488 | 1994-05-06 | ||
PCT/HU1995/000014 WO1995030649A1 (en) | 1994-05-06 | 1995-05-04 | Novel hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2416195A AU2416195A (en) | 1995-11-29 |
AU691284B2 true AU691284B2 (en) | 1998-05-14 |
AU691284C AU691284C (en) | 1999-09-30 |
Family
ID=
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0417210B1 (en) * | 1988-10-20 | 1994-03-09 | Biorex Kutato-Fejlesztö Kft | Novel o-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same |
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0417210B1 (en) * | 1988-10-20 | 1994-03-09 | Biorex Kutato-Fejlesztö Kft | Novel o-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same |
Also Published As
Publication number | Publication date |
---|---|
NO307752B1 (en) | 2000-05-22 |
BG100954A (en) | 1997-08-29 |
DE69504329T2 (en) | 1999-04-08 |
DE69504329D1 (en) | 1998-10-01 |
KR970702845A (en) | 1997-06-10 |
EP0758315B1 (en) | 1998-08-26 |
FI964436A0 (en) | 1996-11-05 |
ES2123252T3 (en) | 1999-01-01 |
BG63336B1 (en) | 2001-10-31 |
NO964677D0 (en) | 1996-11-05 |
KR100372312B1 (en) | 2003-05-09 |
AU2416195A (en) | 1995-11-29 |
PL317154A1 (en) | 1997-03-17 |
FI964436A (en) | 1996-11-27 |
PL179032B1 (en) | 2000-07-31 |
NO964677L (en) | 1996-11-05 |
CZ325196A3 (en) | 1997-06-11 |
EP0758315A1 (en) | 1997-02-19 |
CZ288824B6 (en) | 2001-09-12 |
CN1079789C (en) | 2002-02-27 |
SK281387B6 (en) | 2001-03-12 |
NZ285151A (en) | 1998-09-24 |
WO1995030649A1 (en) | 1995-11-16 |
DK0758315T3 (en) | 1999-05-25 |
RO115873B1 (en) | 2000-07-28 |
SK143096A3 (en) | 1997-06-04 |
CN1151728A (en) | 1997-06-11 |
ATE170170T1 (en) | 1998-09-15 |
JP3877762B2 (en) | 2007-02-07 |
BR9507619A (en) | 1997-09-23 |
EE03296B1 (en) | 2000-10-16 |
JPH09512815A (en) | 1997-12-22 |
MX9605376A (en) | 1998-05-31 |
US5919796A (en) | 1999-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2185381C2 (en) | Amide derivative and pharmaceutical composition | |
AU648394B2 (en) | 4-aryl-thiazole or imidazole derivatives | |
CH649539A5 (en) | ANTIDEPRESSIVE EFFECTIVE PIPERAZINYLALKYL-1,2,4-TRIAZOL-3-ONE. | |
FI112649B (en) | A process for the preparation of therapeutically useful diamine compounds | |
Klayman et al. | 2-Acetylpyridine thiosemicarbazones. 8. Derivatives of 1-acetylisoquinoline as potential antimalarial agents | |
NZ207516A (en) | Thiazolidine derivatives and pharmaceutical compositions | |
IE832058L (en) | 1,4-dihydropyridine derivatives | |
EP0758315B1 (en) | Novel hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same | |
JP2005516898A (en) | Piperazine derivatives having SST1 antagonist activity | |
EP0221511B1 (en) | 2-aminosulfonyl-6-nitrobenzoic esters or amides, process for their preparation and pharmaceutical compositions containing them | |
JPH08502057A (en) | Heterocyclic amines with calmodulin-antagonistic properties | |
CA1241654A (en) | Imidazole derivatives having antimycotic and antibacterial activities, a process for the preparation thereof and pharmaceutical compositions containing them | |
Tatarczyñska et al. | Synthesis, 5-HT1A and 5-HT2A receptor activity of new 1-phenylpiperazinylpropyl derivatives with arylalkyl substituents in position 7 of purine-2, 6-dione | |
JPH05271208A (en) | 1,4-benzothiazepine derivative | |
CA2189652C (en) | Novel hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same | |
US4091219A (en) | Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,3-b]-pyrazine carboxylic acids and esters | |
US6071911A (en) | 4-amino-1-arylpyridin-2-ones and process for making | |
US20030176475A1 (en) | Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical preparations containing them | |
EP3113768B1 (en) | Use of arylalkanolamines as sigma-1 receptor antagonists | |
DK156396B (en) | 2- (N-PYRROLIDINO) -3-ISOBUTOXY-N-SUBSTITUTED PHENYL-N-BENZYL-PROPYLAMINE COMPOUNDS AND PHARMACEUTICAL AGENTS CONTAINING THESE | |
EP1351950B1 (en) | Isoquinolinyl aroyl pyrrole compounds for the treatment of central nervous system disorders | |
CZ327494A3 (en) | Esters of nicotinic acid and process for preparing thereof | |
US4094871A (en) | 1,3,4-Benzotriazepine-2-thiones | |
CA2053980A1 (en) | 4-[4- or 6-(trifluoromethyl-2-pyridinyl)]-1-piperazinyl-alkyl substituted lactams | |
CZ230893A3 (en) | Benzindene derivatives |